Search for: "Mylan Pharmaceuticals, Inc"
Results 441 - 460
of 498
Sorted by Relevance
|
Sort by Date
3 Jul 2022, 6:50 pm
Mylan Pharmaceuticals Inc. 21-1567Issue: Whether 35 U.S.C. [read post]
15 Feb 2011, 5:26 pm
(FDA Law Blog) Diovan (Vasartan) – France: Novartis v Actavis – preliminary injunction for Valsartan confirmed (The SPC Blog) Diovan HTC (Valsartan) – Belgium: Antwerp Court of Appeal stops infringement of Valsartan/HCTZ SPC based on patent claiming Valsartan alone: Novartis v Teva (The SPC Blog) Lescol (Fluvastatin) – US: Novartis files patent infringement complaint against Mylan following Para IV challenge (Patent Docs) (GenericsWeb) Mucinex (Guaifenesin) –… [read post]
3 Jan 2018, 5:10 am
On the heels of the Ericsson decision, further briefing on the waiver issue was recently authorized in Mylan Pharmaceuticals Inc., et al. v. [read post]
18 Feb 2020, 4:00 am
Pfizer Canada ULC, 2020 FC 1, at para. 42. [3] See Sections 27(3)(b) and 28.3 of the Patent Act, RSC 1985, c P-4 [4] Burton Parsons Chemicals, Inc v Hewlett-Packard (Canada) Ltd, [1976] 1 SCR 555 at 563 [5] Apotex Inc v Sanofi-Synthelabo Canada Inc, 2008 SCC 61 at paragraph 37, [2008] 3 SCR 265; see also Bell Helicopter Textron Canada Limitée v Eurocopter, société par actions simplifiée, 2013 FCA 219 at paragraph 65; Mylan… [read post]
9 Apr 2009, 7:52 am
(IP Think Tank) Brazilian public-private partnerships in the pharma industry (IP tango) EU: ECJ to rule on reference on SPC Regulation interpretation from Lithuania in Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras (The SPC Blog) India: Delhi High Court Dasatinib order: Is patent-drug regulatory linkage a necessity? [read post]
9 Aug 2021, 2:22 pm
Scilex Pharmaceuticals Inc. v. [read post]
3 Oct 2018, 8:51 am
Mylan Pharmaceuticals). [read post]
6 Jul 2011, 2:21 am
Biopet Vet Lab, Inc., et. al. [read post]
25 Jan 2007, 12:48 am
Friedlander, 103 F.3d 1105, 1113 (2d Cir. 1997); Mylan Laboratories, Inc. v. [read post]
23 Dec 2007, 8:00 pm
You can separately subscribe to the IP Thinktank Global week in Review at [feeds.feedburner.com]GlobalEvents in Bali heap further pressure on all IP owners: (IAM),Velcro defies generic claim in domain name battle: (OUT-LAW),ICANN forms group to hasten non-English domain names: (IP Justice)WTO members continue debate on geographical indications register: (Intellectual Property Watch),Creative Commons launches CCo and CC programs: (World IP Day),Green IP Strategy - risks… [read post]
1 Oct 2009, 2:14 am
Mylan Pharmaceuticals, 2008 WL 3540462 (N.D.W. [read post]
1 Nov 2017, 2:58 pm
See also, 16-712bsacAAM; and 16-712 bsac America’s Health Insurance Plans; 16-712 bsac Mylan Pharmaceuticals Inc_ (“Mylan’s experiences with inter partes review highlight the pro-competitive nature of inter partes review. [read post]
15 Sep 2016, 4:00 am
Mylan Pharmaceuticals ULC, 2015 FC 125 at paragraph 154, to assist with determining whether a feature was an instruction on how to administer a dosage or an aspect of the dosage form itself for determining whether a claim was patentable subject matter or a method medical treatment. [read post]
28 Jun 2007, 10:16 am
Pfizer, Inc., ___ F. [read post]
5 Nov 2015, 6:00 am
Mylan Pharmaceuticals Inc. v. [read post]
22 Feb 2008, 6:00 pm
Signature Financial Group, Inc., and AT&T Corp. v. [read post]
26 Dec 2017, 7:08 pm
Mylan paid approximately $231.7 million to the federal government and $213.9 million to state Medicaid programs. [read post]
27 Sep 2009, 5:13 pm
Asssociates, Inc. [read post]
13 Mar 2024, 7:24 pm
., Inc. v. [read post]
25 Jul 2008, 7:04 am
, (Daily Dose of IP), 26 August: WIPO symposium on IP and multilateral agreements – Geneva: (IPKat), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop –… [read post]
